RxDoctor Payments Data

Douglas Slater, MD

Internal Medicine · Rocky Mount, NCNPI 1578557393

Payments from drug & device makers

$368in general payments, 2019–2025

Across 19 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$55
  • AstraZeneca$50
  • GSK$47
  • Boehringer Ingelheim$47
  • Abbott$42
  • Amgen$27
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$35496%
  • Education$144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$368 in reported general payments places this provider in the 60th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$247,396
Medicare patients
520
Services billed
3,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide242$357,876
JardianceEmpagliflozin270$301,512
EliquisApixaban256$281,269
FarxigaDapagliflozin Propanediol116$131,687
MounjaroTirzepatide96$118,099
XareltoRivaroxaban76$94,243
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$87,732
Tresiba Flextouch U-200Insulin Degludec76$70,566
JanuviaSitagliptin Phosphate56$52,479
EntrestoSacubitril/Valsartan27$40,878
LinzessLinaclotide43$30,945
InvokanaCanagliflozin12$20,745
GemtesaVibegron25$20,550
SynjardyEmpagliflozin/Metformin Hcl17$20,212
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$17,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$55$357,876242 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$47$329,732298 claims
AstraZenecaFarxiga, Breztri Aerosphere$50$146,296132 claims
GSKTrelegy Ellipta, Breo Ellipta$47$102,83892 claims
AbbVieLinzess$15$30,94543 claims
Sumitomo Pharma America, Inc.Gemtesa$12$20,55025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →